Navigation Links
KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
Date:11/7/2013

s for the CF indication and has initiated a 180 patient Phase 2 study in CF subjects with chronic Pa lung infection in the United States. KaloBios has received Orphan Drug designation from both the FDA and the European Commission for KB001-A for the treatment of CF patients with Pa lung infection. Sanofi is pursuing a ventilator-associated pneumonia prevention indication in the intensive care setting, an indication which has received U.S. FDA Fast Track Designation.
  • KB004, an anti-EphA3 mAb, has potential in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in subjects with hematologic malignancies. KaloBios plans to begin the phase 2 portion of this study in AML and MDS before the end of 2013.
  • All of the company's antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered® technology offer important clinical and economic advantages over antibodies generated by other methods in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration in humans.

    For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.

    Forward Looking Statements

    This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: the statements under the heading "Anticipated Upcoming Milestones for 2013-2014"; and statements regarding the company's clinical development of
    '/>"/>

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology news :

    1. Cell therapy using patients own bone marrow may present option for heart disease
    2. Report presents designs for study of cancer risks near US nuclear facilities
    3. Entomology 2012 to present 105 insect symposia in November
    4. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
    5. The Brain Prize 2012 is presented May 9th
    6. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
    7. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
    8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
    9. Coral reef experts to present latest coral reef science during July symposium
    10. FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium
    11. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/31/2014)... good for attracting species, but it may not be enough ... study has found. , The researchers surveyed two types of ... abundance of two insects that interact with them. They found ... and black walnut, they didn,t find a corresponding abundance of ... the walnuts and black cherries and a type of wasp ...
    (Date:10/31/2014)... 30, 2014  HITLAB SM , a healthcare ... its inaugural HITLAB Innovators Summit SM on ... HITLAB will partner with the Clinton Foundation,s Health ... ProtoHack, Columbia Business School Alumni Club of ... Engineering and Operations Research, bringing together leaders in ...
    (Date:10/30/2014)... 2014—Oligonucleotide-based therapeutics present unique challenges when it comes ... developmental harm. New consensus guidelines for toxicity testing ... biological characteristics of these novel biopharmaceuticals are presented ... journal from Mary Ann Liebert, Inc. publishers ... Nucleic Acid Therapeutics website until November ...
    Breaking Biology News(10 mins):Green spaces don't ensure biodiversity in urban areas 2HITLAB Announces Inaugural HITLAB Innovators Summit 2HITLAB Announces Inaugural HITLAB Innovators Summit 3New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2
    ... Institute of Nanoscience have discovered how to use the ... a chip. Based on this, they built a transport ... individually. To demonstrate this, the Delft researchers sorted the ... the University of Florida has called the Delft discovery ...
    ... working at the University of Bristol has found a ... food poisoning. Their work is reported in Nature Medicine. ... shown that one particular antibiotic ? fosfomycin ?can treat ... laboratory conditions. , Because it was not effective in ...
    ... Wegener Institute for Polar and Marine Research observed ... began in Ny-Ålesund on Svalbard. Monitoring instruments displayed ... found. Aerosols from eastern Europe have been transported ... large-scale weather situation. , Usually the air ...
    Cached Biology News:Biological motors sort molecules one by one on a chip 2Record air pollution above the Arctic 2
    (Date:10/31/2014)... (PRWEB) October 30, 2014 Two ... America were hosted by Charm Sciences at its ... their week in the US, the participants discussed ... control, hygiene management, and process verification, and received ... , This was the first visit to the ...
    (Date:10/31/2014)... October 31, 2014 Following the successful ... free learning webinar to introduce its new product and ... and biostatisticians. , Launched in September, Formedix On Demand ... of clinical trial automation tools. For the first time, ... browser. And by introducing Formations – a revolutionary new ...
    (Date:10/31/2014)... The report "Dairy Alternative (Beverage) Market ... Sweetened, Unsweetened), Channel (Supermarket, Health Store, Pharmacy, Convenience ... to 2018," defines and segments the dairy alternative ... revenue and volume for plant-based dairy alternative beverages. ... $14 Billion by 2018 with the Asia-Pacific region ...
    (Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
    Breaking Biology Technology:Charm Sciences Hosts Executives from Latin America for Dairy Safety Executive Seminar 2Formedix to Introduce "Revolutionary" Clinical Trial Automation Software with Learning Webinar 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 2Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 3Dairy Alternative Beverage Market Projected to Reach $14 Billion by 2018 - Report by MarketsandMarkets 4Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3
    ... ST PETER PORT, Guernsey and LONDON, July 6 ... to Drive Novel Antibiotics Platform Addressing,Areas of Major Unmet Need, ... Celtic Pharma Holdings Advisors LLP ("CPHA"), the advisor ... ("CP2"), today announces its,investment in a majority shareholding in Novacta ...
    ... NEW BRUNSWICK, N.J., July 3 Johnson & Johnson (NYSE: ... its tender offer for all outstanding shares of common stock of ... (Eastern time) on July 2, 2009. The offer was conducted ... Merger Sub, Inc. , , The depositary for the tender ...
    ... , PHOENIX, July 2 As many as ... with an eating disorder because they,re ashamed to admit they ... Eating and Anxiety Disorders . Healthcare professionals, family members ... in males that may signify an eating disorder. Therefore, effective ...
    Cached Biology Technology:Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 2Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 3Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 4Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited 5Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 2Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 3Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology 4Remuda Ranch Programs for Eating and Anxiety Disorders Reports Need for Increasing Awareness of Eating Disorders in Males 2